Searching News Database: Toll-like receptor
HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
HSMN NewsFeed - 10 Nov 2020
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
Cytocom, Inc. Appoints Taunia Markvicka, PharmD., MBA, Chief Operating Officer
HSMN NewsFeed - 6 Feb 2017
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
HSMN NewsFeed - 10 Jul 2013
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
Idera Pharmaceuticals Appoints James Geraghty as Chairman of the Board of Directors
HSMN NewsFeed - 30 Apr 2013
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors
Dynavax Names Eddie Gray as Chief Executive Officer and Member of the Board of Directors
HSMN NewsFeed - 23 Apr 2013
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
HSMN NewsFeed - 25 Feb 2013
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application
Dynavax Receives FDA Complete Response Letter on HEPLISAV(TM) Biologic License Application
HSMN NewsFeed - 9 Oct 2012
Cytos Biotechnology Ltd appoints Dr. Christian Itin as Chief Executive Officer
Cytos Biotechnology Ltd appoints Dr. Christian Itin as Chief Executive Officer
HSMN NewsFeed - 14 Dec 2010
FDA Grants Hemispherx Biopharma Extension in Its Pending NDA for Treatment of Chronic Fatigue Syndrome (CFS)
FDA Grants Hemispherx Biopharma Extension in Its Pending NDA for Treatment of Chronic Fatigue Syndrome (CFS)
HSMN NewsFeed - 26 Jan 2010
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
Idera Pharmaceuticals Announces the Appointment of Malcolm MacCoss, Ph.D., to Its Board of Directors
HSMN NewsFeed - 12 Jan 2010
VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing
VentiRx Pharmaceuticals Raises $25 Million in Series A Extension Financing
HSMN NewsFeed - 19 May 2009
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
Roche Venture Fund, Enterprise Ireland Commit EUR3.3 M to Opsona Series B Financing
HSMN NewsFeed - 1 Apr 2008
Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
Pfizer Announces Discontinuation of Phase III Clinical Trial for Patients with Advanced Melanoma
HSMN NewsFeed - 19 Sep 2007
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
HSMN NewsFeed - 21 May 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
HSMN NewsFeed - 12 Apr 2007
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
Coley Pharmaceutical Group Licenses VaxImmune(TM) to Merck for Use in Vaccine Programs
HSMN NewsFeed - 21 Feb 2007
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
Idera Pharmaceuticals Appoints Dr. Alice Bexon, Vice President of Clinical Development
HSMN NewsFeed - 17 Jan 2007
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
John Z. Sullivan-Bolyai, M.D., MPH, Joins Anadys Pharmaceuticals as Vice President, Clinical Affairs
HSMN NewsFeed - 28 Dec 2006
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
SciClone and Sigma-Tau Complete Enrollment in Phase 3 Triple Therapy Hepatitis C Clinical Trial
HSMN NewsFeed - 22 Dec 2006
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
SciClone and Sigma-Tau Announce Positive Interim Survival Data From Large Phase 2 Malignant Melanoma Trial
HSMN NewsFeed - 20 Dec 2006
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
HSMN NewsFeed - 28 Nov 2006
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Results in Phase 3 Trial
HSMN NewsFeed - 20 Nov 2006
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
Anadys Pharmaceuticals Names Lawrence C. Fritz, Ph.D., as President and Chief Executive Officer
HSMN NewsFeed - 4 Oct 2006
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
NEW ENGLAND JOURNAL OF MEDICINE Reports Positive Results From Dynavax' Ragweed Allergy Therapy Trial
HSMN NewsFeed - 11 Jul 2006
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer
James L. Freddo, M.D., Joins Anadys Pharmaceuticals as Chief Medical Officer
Additional items found! 38
Members Archive contains
38 additional stories matching:
Toll-like receptor
(Password required)
Toll-like receptor
(Password required)
